NCT00311415View on ClinicalTrials.gov

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Prevention of Meningococcal Infection
Interventions
BIOLOGICAL

Meningococcal C conjugate vaccine

"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"

Trial Locations (2)

Unknown

Mainz, Kehl, Neumünster, Ettenheim

Kraków, Lubartów, Lublin, Bydgosczcz

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY